These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

228 related articles for article (PubMed ID: 27503625)

  • 41. Immunogenicity and safety of human papillomavirus-16/18 AS04-adjuvanted cervical cancer vaccine in healthy Indian women.
    Bhatla N; Suri V; Basu P; Shastri S; Datta SK; Bi D; Descamps DJ; Bock HL;
    J Obstet Gynaecol Res; 2010 Feb; 36(1):123-32. PubMed ID: 20178538
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Human papillomavirus vaccination in adolescence.
    Russell M; Raheja V; Jaiyesimi R
    Perspect Public Health; 2013 Nov; 133(6):320-4. PubMed ID: 24006173
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Cervical cancer vaccination indications, efficacy, and side effects.
    Bayas JM; Costas L; Muñoz A
    Gynecol Oncol; 2008 Sep; 110(3 Suppl 2):S11-4. PubMed ID: 18586311
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Comparison of the immunogenicity and reactogenicity of Cervarix and Gardasil human papillomavirus vaccines in HIV-infected adults: a randomized, double-blind clinical trial.
    Toft L; Storgaard M; Müller M; Sehr P; Bonde J; Tolstrup M; Østergaard L; Søgaard OS
    J Infect Dis; 2014 Apr; 209(8):1165-73. PubMed ID: 24273179
    [TBL] [Abstract][Full Text] [Related]  

  • 45. A sudden onset of a pseudo-neurological syndrome after HPV-16/18 AS04-adjuvated vaccine: might it be an autoimmune/inflammatory syndrome induced by adjuvants (ASIA) presenting as a somatoform disorder?
    Poddighe D; Castelli L; Marseglia GL; Bruni P
    Immunol Res; 2014 Dec; 60(2-3):236-46. PubMed ID: 25388965
    [TBL] [Abstract][Full Text] [Related]  

  • 46. CNS demyelination and quadrivalent HPV vaccination.
    Sutton I; Lahoria R; Tan I; Clouston P; Barnett M
    Mult Scler; 2009 Jan; 15(1):116-9. PubMed ID: 18805844
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Clinical trial and post-licensure safety profile of a prophylactic human papillomavirus (types 6, 11, 16, and 18) l1 virus-like particle vaccine.
    Block SL; Brown DR; Chatterjee A; Gold MA; Sings HL; Meibohm A; Dana A; Haupt RM; Barr E; Tamms GM; Zhou H; Reisinger KS
    Pediatr Infect Dis J; 2010 Feb; 29(2):95-101. PubMed ID: 19952863
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Cost-effectiveness analysis of the introduction of the human papillomavirus vaccine in Honduras.
    Aguilar IB; Mendoza LO; García O; Díaz I; Figueroa J; Duarte RM; Perdomo G; Garcia AG; Janusz CB
    Vaccine; 2015 May; 33 Suppl 1():A167-73. PubMed ID: 25919157
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Human Papillomavirus Vaccine and Postural Orthostatic Tachycardia Syndrome: A Review of Current Literature.
    Butts BN; Fischer PR; Mack KJ
    J Child Neurol; 2017 Oct; 32(11):956-965. PubMed ID: 28689455
    [TBL] [Abstract][Full Text] [Related]  

  • 50. The GARDASIL vaccine can prevent cervical carcinoma caused by human papilloma virus (HPV) (results from our participation and from the study carried out in Greece).
    Ansstasiou-Fotaki P; Deligeoroglou E; Kreatsas G
    Akush Ginekol (Sofiia); 2007; 46(3):17-20. PubMed ID: 18018777
    [TBL] [Abstract][Full Text] [Related]  

  • 51. FDA licensure of bivalent human papillomavirus vaccine (HPV2, Cervarix) for use in females and updated HPV vaccination recommendations from the Advisory Committee on Immunization Practices (ACIP).
    Centers for Disease Control and Prevention (CDC)
    MMWR Morb Mortal Wkly Rep; 2010 May; 59(20):626-9. PubMed ID: 20508593
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Immunogenicity of quadrivalent HPV and combined hepatitis A and B vaccine when co-administered or administered one month apart to 9-10 year-old girls according to 0-6 month schedule.
    Gilca V; Sauvageau C; Boulianne N; De Serres G; Couillard M; Krajden M; Ouakki M; Murphy D; Trevisan A; Dionne M
    Hum Vaccin Immunother; 2014; 10(8):2438-45. PubMed ID: 25424952
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Sustained immunogenicity of the HPV-16/18 AS04-adjuvanted vaccine administered as a two-dose schedule in adolescent girls: Five-year clinical data and modeling predictions from a randomized study.
    Romanowski B; Schwarz TF; Ferguson L; Peters K; Dionne M; Behre U; Schulze K; Hillemanns P; Suryakiran P; Thomas F; Struyf F
    Hum Vaccin Immunother; 2016; 12(1):20-9. PubMed ID: 26176261
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Risk of autoimmune diseases and human papilloma virus (HPV) vaccines: Six years of case-referent surveillance.
    Grimaldi-Bensouda L; Rossignol M; Koné-Paut I; Krivitzky A; Lebrun-Frenay C; Clet J; Brassat D; Papeix C; Nicolino M; Benhamou PY; Fain O; Costedoat-Chalumeau N; Courcoux MF; Viallard JF; Godeau B; Papo T; Vermersch P; Bourgault-Villada I; Breart G; Abenhaim L;
    J Autoimmun; 2017 May; 79():84-90. PubMed ID: 28190705
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Long-term persistence of systemic and mucosal immune response to HPV-16/18 AS04-adjuvanted vaccine in preteen/adolescent girls and young women.
    Petäjä T; Pedersen C; Poder A; Strauss G; Catteau G; Thomas F; Lehtinen M; Descamps D
    Int J Cancer; 2011 Nov; 129(9):2147-57. PubMed ID: 21190190
    [TBL] [Abstract][Full Text] [Related]  

  • 56. [Active surveillance evaluation of anti-HPV vaccine adverse events in Umbria region].
    Gianfredi V; Paoloni MC; Villarini M; Moretti M
    Clin Ter; 2017; 168(5):e327-e332. PubMed ID: 29044356
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Quadrivalent HPV vaccination reactions--more hype than harm.
    Douglas RJ
    Aust Fam Physician; 2009 Mar; 38(3):139-42. PubMed ID: 19283255
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Developing an HPV vaccine to prevent cervical cancer and genital warts.
    Bryan JT
    Vaccine; 2007 Apr; 25(16):3001-6. PubMed ID: 17289220
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Prevention of human papillomavirus infections and associated diseases by vaccination: a new hope for global public health.
    Harper DM
    Public Health Genomics; 2009; 12(5-6):319-30. PubMed ID: 19684444
    [TBL] [Abstract][Full Text] [Related]  

  • 60. No increased risk of Guillain-Barré syndrome after human papilloma virus vaccine: A self-controlled case-series study in England.
    Andrews N; Stowe J; Miller E
    Vaccine; 2017 Mar; 35(13):1729-1732. PubMed ID: 28245941
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.